Hypocholesterolemia and Statins in Multiple Myeloma
Irfan Yavaşoğlu *
Hematologist, Aydin Adnan Menderes University Medical Faculty, Division of Hematology, Aydin, Turkey.
Atakan Turgutkaya
Hematologist, Aydin Adnan Menderes University Medical Faculty, Division of Hematology, Aydin, Turkey.
*Author to whom correspondence should be addressed.
Abstract
Statins are lipid-lowering agents. They also have immunomodulatory, anti-inflammatory, anti-angiogenic, and anti-proliferative functions. In this context, they are demonstrated to have beneficial effects on mortality in several malignancies including esophageal, breast, lung, liver, pancreatic, endometrial, and colorectal cancers. Multiple myeloma is considered as an incurable plasma cell disorder with current therapy; however due to the current knowledge about the correlation between cholesterol-lowering agents and myeloma; it’s suggested to have lower mortality rates for patients using statins. Patients with multiple myeloma usually have a low cholesterol level which is often underestimated by clinicians. Hereby we aimed to summarize the myeloma-hypocholesterolemia relationship and emphasize the importance of statins as an inexpensive and beneficial approach for these patients.
Keywords: Cell line, cholesterol, LDL, multiple myeloma, proteasome, statins